SEARCH

SEARCH BY CITATION

References

  • 1
    Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med, 2002; 31: 334339.
  • 2
    Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006; 44: 353358.
  • 3
    Aslam S, Hamill RJ, Musher DM. Treatment of CDAD: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549557.
  • 4
    Songer JG. The emergence of Clostridium difficile as a pathogen of food animals. Animal Health Res Rev 2005; 5: 321326.
  • 5
    Mcfarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriers and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162: 678684.
  • 6
    Chernakl E, Johnson CC, Weltman A et al. Severe Clostridium difficile-associated disease in populations previously at low risk—four states. MMWR 2005; 54: 12011205.
  • 7
    Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 204: 29892995.
  • 8
    Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981; 81: 59.
  • 9
    Mcfarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204210.
  • 10
    Kim KH, Fekety R, Batts DH et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143: 4250.
  • 11
    Samore MH, Venkataraman L, Degirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial CDAD. Am J Med 1996; 100: 3240.
  • 12
    Verity P, Wilcox MH, Fawley W, Parnell P. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms. J Hosp Infect 2001; 49: 204209.
  • 13
    Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003; 54: 109114.
  • 14
    Kaatz GW, Gitlin SD, Schaberg DR, Wilson KH, Kauffman CA, Seo SM. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988; 127: 12891293.
  • 15
    Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31: 9951000.
  • 16
    Fawley WN, Wilcox MH. Molecular epidemiology of endemic Clostridium difficile infection. Epidemiol Infect 2001; 126: 343350.
  • 17
    Rupnik M, Dupuy B, Fairweather NF et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol 2005; 54: 113117.
  • 18
    Alfa MJ, Kabani A, Lyerly D et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 27062714.
  • 19
    Kuijper EJ, De Weerdt J, Kato H et al. Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis 2001; 20: 528534.
  • 20
    Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004; 42: 19331939.
  • 21
    Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56: 22992306.
  • 22
    Rupnik M, Grabner M, Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe 2003; 9: 289294.
  • 23
    Geric B, Carman RJ, Rupnik M et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006; 193: 11431151.
  • 24
    Sebaihia M, Wren B, Mullany P et al. The multidrug resistant human pathogen Clostridium difficile has a highly, mobile mosaic genome. Nat Genet 2006; 38: 779786.
  • 25
    Delmee M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect 2001; 7: 411416.
  • 26
    Barbut F, Delmée M, Brazier JS et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003; 9: 989996.
  • 27
    Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739750.
  • 28
    National Clostridium difficile Standards Group. Report to the Department of Health. J Hosp Infect 2004; 56: 138.
  • 29
    Van Den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, Endtz HP, Van Der Vorm ER, Kuijper EJ. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol 2005; 43: 53385340.
  • 30
    Van Den Berg RJ, Kuijper EJ, Van Coppenraet LE, Claas EC. Rapid diagnosis of toxinogenic Clostridium difficile in faecal samples with internally controlled real-time PCR. Clin Microbiol Infect 2006; 12: 184186.
  • 31
    Belanger SD, Boissinot M, Clairoux N, Picard FJ, Bergeron MG. Rapid detection of Clostridium difficile in feces by real-time PCR. J Clin Microbiol 2003; 41: 730734.
  • 32
    Kuhl SJ, Tang YL, Navarro L, Gumerlock PH, Silva Jr J. Diagnosis and monitoring of Clostridium difficile infections with the polymerase chain reaction. Clin Infect Dis 1993; 16: S234S238.
  • 33
    Kato N, Ou CY, Kato H et al. Detection of toxinogenic C. difficile in stool specimen by the polymerase chain reaction. J Infect Dis 1993; 167: 455458.
  • 34
    Anonymous. Deaths involving Clostridium difficile: England and Wales, 1999–2004. Health Statistics Q 2006; 30: 5660.
  • 35
    Peláez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46: 16471650.
  • 36
    Peláez T, Alcalá L, Alonso R, Martín-López M, García-Arias V, Bouza E. In vitro activity of ramoplanin against C. difficile including strains with reduced suspectibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005; 49: 11571159.
  • 37
    Bishara J, Bloch Y, Garty M, Behor J, Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006; 54: 141144.
  • 38
    Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346353.
  • 39
    Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M, Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002; 23: 137140.
  • 40
    Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 (suppl C): 512.
  • 41
    Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital acquired Clostridium difficile infection. J Hosp Infect 1996; 34: 2330.
  • 42
    Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 12541260.
  • 43
    Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease. Clin Infect Dis 2006; 42: 758764.
  • 44
    Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004; 171: 466472.
  • 45
    Eggertson L. C. difficile: by the numbers. Can Med Assoc J 2004; 171: 13311332.
  • 46
    Eggertson L. Quebec puts up $20 millions for C. difficile fight. Can Med Assoc J 2005; 172: 622.
  • 47
    Comité sur les infections nosocomiales du Québec. Prévention et contrôle de la diarrhée nosocomiale associée au Clostridium difficile au Québec—Lignes directrices pour les établissements de soins, 3rd edn. Institut national de santé publique du Québec. 2005. http://www.inspq.qc.ca/pdf/publications/362-CDifficile-LignesDirectrices-3eEdition.pdf
  • 48
    Gilca R, Fortin E, Hubert B, Frenette C, Gourdeau M. Surveillance des diarrhées associées à Clostridium difficile au Québec—Bilan Du 22 août 2004 au 20 août. Institut national de santé publique du Québec. 2005. http://www.inspq.qc.ca/pdf/publications/434-BilanCdifficile-22aout2004-20aout2005.pdf
  • 49
    Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 24422449.
  • 50
    Wilcox MH, Freeman J. Epidemic Clostridium difficile. N Engl J Med 2006; 354: 11991203.
  • 51
    Eggertson L. Quebec strain of C. difficile in 7 provinces. Can Med Assoc J 2006; 174: 607608.
  • 52
    Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis 2004; 189: 15851589.
  • 53
    Mcdonald LC, Owings M, Jernigan DB. Increasing rates of Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 2006; 12: 409415.
  • 54
    Mcdonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 24332441.
  • 55
    Rupnik M, Avesani V, Janc M, Von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36: 22402247.
  • 56
    Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 10791084.
  • 57
    Anonymous. Outbreak of Clostridium difficile in a hospital in south east England. CDR Weekly 2005; 15; no. 24.
  • 58
    Smith A. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Eurosurveillance 2005; 10: 050630. http://www.eurosurveillance.org/ew/2005/050630asp#2
  • 59
    Kuijper EJ, Debast SB, Van Kregten E, Vaessen N, Notermans DW, Van Den Broek PJ. Clostridium difficile ribotype 027, toxinotype III in the Netherlands. Ned Tijdschr Geneeskd 2005; 49: 20872089.
  • 60
    Kuijper EJ, Van Den Berg R, Debast S et al. Clostridium difficile ribotype 027, toxinotype III in The Netherlands. Emerg Infect Dis 2006; 12: 827830.
  • 61
    Van Steenbergen J, Debast S, Van Kregten E, Van Den Berg R, Notermans D, Kuijper EJ. Isolation of Clostridium difficile ribotype 027, toxinotype III in the Netherlands after increase in C. difficile-associated diarrhoea. Eurosurveill Weekly 2005 10: E050714.1. Available from: http://www.eurosurveillance.org/ew/2005/050714.asp#1
  • 62
    Notermans D, Van Kregten E, Speelman P, Kuijper E, namens het 36e Outbreak management team (OMT) dd 7 juli. Maatregelen bij een epidemische verheffing in een ziekenhuis door Clostridium difficile ribotype 027–toxinotype III. http://www.infectieziekten.info/index.php3 and http://www.nvmm.nl/index.htm
  • 63
    Krausz S, Bessems M, Boermeester MA, Kuijper E, Visser CE, Speelman P. Life-threatening infections with a new strain of Clostridium difficile. Ned Tijdschr Geneeskd 2005; 149: 20812086.
  • 64
    Van Den Hof S, Van Der Kooi T, Van Den Berg R, Kuijper E, Notermans D. Clostridium difficile PCR ribotype 027 outbreaks in the Netherlands: recent surveillance data indicate that outbreaks are not easily controlled but interhospital transmission is limited. Euro Surveill 2006; 11: E060126.2 http://www.eurosurveillance.org/ew/2006/060126.asp#2
  • 65
    Joseph R, Demeyer D, Vanrenterghem D, Van Den Berg R, Kuijper EJ, Delmée M. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Eurosurveill Weekly 2005; 10: E051020.4. Available from: http://www.eurosurveillance.org/ew/2005/051020.asp#4
  • 66
    Tachon M, Cattoen C, Blanckaert K et al. First cluster of C. difficile toxinotype III, PCR-ribotype 027 associated disease in France: preliminary report. Eurosurveillance 2006; 11: E060504.1. Available from: http://www.eurosurveillance.org/ew/2006/060504.asp#1
  • 67
    Stubbs SL, Brazier J, O'Neill GL, Duerden BI. PCR targeted to the 16S−23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461463.
  • 68
    Braun V, Hundesberger T, Leukel P, Sauerborn M, Von Eichel-Streiber C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 1996; 181: 2938.
  • 69
    Bidet P, Lalande V, Salauze B et al. Comparison of PCR-ribotyping, arbitrarily primed PCR and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 8: 24842487.
  • 70
    Maccannell DR, Louie TJ, Gregson DB et al. Molecular analysis of Clostridium difficile PCR, ribotype 027 isolates from eastern and western Canada. J Clin Microbiol 2006; 44: 21472152.
  • 71
    Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 2004; 53: 887894.
  • 72
    Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SL. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 2001; 147: 439447.
  • 73
    Clabots CR, Johnson S, Bettin KM et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 1993; 31: 18701875.
  • 74
    Kuijper EJ, Oudbier JH, Stuifbergen WN, Jansz A, Zanen HC. Application of whole-cell DNA restriction endonuclease profiles to the epidemiology of Clostridium difficile-induced diarrhea. J Clin Microbiol 1987; 25: 751753.
  • 75
    Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002; 40: 34703475.
  • 76
    Anonymous. Results of the first year of mandatory Clostridium difficile reporting: January to December 2004. CDR Weekly 2005; 15: 13.
  • 77
    Lai KK, Melvin ZS, Menard MJ et al. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol 1997; 18: 628632.
  • 78
    John R, Brazier JS. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 2005; 61: 1114.
  • 79
    Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 23862388.
  • 80
    Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159: 340343.
  • 81
    O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991; 107: 627635.
  • 82
    Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection—relapse or reinfection? J Hosp Infect 1998; 38: 93100.
  • 83
    Van Den Berg RJ, Ameen HA, Furusawa T, Claas EC, Van Der Vorm ER, Kuijper EJ. Coexistence of multiple PCR-ribotype strains of Clostridium difficile in faecal samples limits epidemiological studies. J Med Microbiol 2005; 54: 173179.
  • 84
    Ho JG, Greco A, Rupnik M, Ng KK. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci USA, 2005; 102: 1837318378.
  • 85
    Reinert DJ, Jank T, Aktories K, Schulz GE. Structural basis for the function of Clostridium difficile toxin B. J Mol Biol 2005; 351: 973981.